Evaluation of indapamide in the treatment of hypertension.

J Cardiovasc Pharmacol, 1979/7-1979/8;1(4):389-94.

Anavekar SN, Ludbrooke A, Louis WJ, Doyle AE

PMID: 94616

Impact factor: 3.271

Abstract
A randomized double-blind, crossover trial was carried out in twenty hypertensive patients to evaluate the hypotensive efficacy and safety of indapamide. Indapamide in doses of 2.5 mg per day in combination with other antihypertensive agents was as effective in reducing the blood pressure in hypertensive patients as one tablet of Moduretic (50 mg hydrochlorothiazide and 5 mg amiloride). Indapamide induced no changes in serum potassium or uric acid levels and there were no major side effects.
MeSH terms
More resources
EndNote: Download